(Q44080878)

29 November 2017

title

Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction (English)

1 reference

29 November 2017

0 references

1 reference

5

Butterworth RF

1 reference

29 November 2017

Pomier-Layrargues G

1

1 reference

29 November 2017

Giguère JF

series ordinal

2

1 reference

29 November 2017

Lavoie J

series ordinal

3

1 reference

29 November 2017

Willems B

series ordinal

4

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 December 1989

1 reference

29 November 2017

1 reference

29 November 2017

volume

10

1 reference

29 November 2017

issue

6

1 reference

29 November 2017

page(s)

969-972

1 reference

Supersensitivity of Benzodiazepine Receptors in Hepatic Encephalopathy Due to Fulminant Hepatic Failure in the Rat: Reversal by a Benzodiazepine Antagonist

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABAA-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Improvement of hepatic encephalopathy treated with flumazenil

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Highly sensitive assay of benzodiazepine antagonist in plasma by capillary gas chromatography with nitrogen-selective detection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity and therapeutic use.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Plasma GABA, GABA-like activity and the brain GABA-benzodiazepine receptor complex in rats with chronic hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Affinities and densities of high-affinity [3H]muscimol (GABA-A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840100613

7 January 2021

Identifiers

DOI

10.1002/HEP.1840100613

1 reference

29 November 2017

1 reference